Concise Biothiol-Activatable HPQ-NBD Conjugate as a Targeted Theranostic Probe for Tumor Cells.
Yan ZhangCaiyun LiuWeimin SunZiwen YuMeijun SuXiaodi RongXin WangKun WangXiwei LiHanchuang ZhuMiaohui YuWenlong ShengBao-Cun ZhuPublished in: Analytical chemistry (2022)
Cancer, as a malignant tumor, seriously endangers human health. The study of cancer diagnosis and therapy has great practical significance. The development of theranostic agents has become a very important research topic. Nevertheless, some existing agents still have imperfections, such as complex structures and difficult syntheses. Therefore, it is urgent for researchers to develop simple novel theranostic agents. In this study, the precipitated fluorophore HAPQ was used as a simple drug molecule for the first time and combined with NBD-Cl to construct a simple and efficient theranostic probe ( HAPQ-NBD ). The theranostic probe can distinguish between tumor cells and normal cells based on the higher levels of biothiol in tumor cells. In addition, the probe can use biothiol as a control switch to release higher levels of precipitated fluorophore HAPQ in tumor cells, leading to selective high toxicity to tumor cells, thus achieving the goal of selectively killing tumor cells. The construction of probe HAPQ-NBD provides a practical tool for the diagnosis and therapy of cancer. It is expected that the development and utilization of precipitated fluorophore will provide a new method and strategy for cancer diagnosis and therapy.
Keyphrases
- papillary thyroid
- living cells
- photodynamic therapy
- squamous cell
- fluorescence imaging
- fluorescent probe
- human health
- risk assessment
- emergency department
- lymph node metastasis
- oxidative stress
- squamous cell carcinoma
- cancer therapy
- drug delivery
- stem cells
- cell death
- young adults
- high resolution
- climate change
- iron oxide
- replacement therapy